Galectin Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Galectin Therapeutics

14/11/2022 15:20

* Galectin Therapeutics Inc  GALT.OQ  reported a quarterly
adjusted loss of 14 cents​​ per share for the quarter ended in
September. The lone analyst forecast for the quarter was for a
loss of 20 cents per share.
    * Reported revenue was zero​. 
    * Galectin Therapeutics Inc's reported EPS for the quarter
was a
loss of 14 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Galectin Therapeutics Inc shares had fallen by 25.0% this
quarter and lost 41.0% so far this year.
    * The company reported a quarterly loss of $8.58 million.
    * Wall Street's median 12-month price target for Galectin
Therapeutics Inc is $11.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
14 at 03:20 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.20          -0.14          Beat
 Jun. 30 2022      -0.19          -0.16          Beat
 Mar. 31 2022      -0.14          -0.17          Missed
 Dec. 31 2021      -0.19          -0.12          Beat